William Schuyler Jones

William Schuyler Jones

Associate Professor of Medicine

I am an interventional cardiologist with a specific focus on the diagnosis and treatment of patients with cardiovascular disease. As a clinician, I see patients in the office and do coronary and peripheral vascular procedures (angiography and interventions) in the Duke Cardiac Catheterization Laboratory. I have served as the Medical Director of the cath lab at Duke since 2016. Alongside my partners in the cath lab, we collaborate with our cardiothoracic surgeons to hold Heart Team meetings each week, and we frequently are asked to address complex cardiovascular issues as a multidisciplinary team.

I also have a broad background in cardiovascular site-based research, multicenter clinical trials, clinical event classification, and observational analyses. I have helped to lead clinical trial efforts at the Duke Clinical Research Institute (DCRI) by designing and conducting studies evaluating new and existing treatments for patients with coronary artery disease and peripheral artery disease. My specific research interests include examining access to care and disparities in care for patients with peripheral artery disease and the design and conduct of pragmatic clinical trials in cardiovascular disease.

Appointments and Affiliations

  • Associate Professor of Medicine
  • Associate Professor in Population Health Sciences
  • Member of the Duke Clinical Research Institute

Contact Information

  • Office Location: 2400 Pratt Street, 7037, Durham, NC 27705
  • Office Phone: (919) 668-8917
  • Email Address: schuyler.jones@duke.edu


  • Duke University, 2005
  • Duke University, 2004
  • M.D. University of Arkansas, Little Rock, 2001

Representative Publications

  • Krawisz, AK; Raja, A; Jones, WS; Schneider, P; Shen, C; Schermerhorn, M; Secemsky, EA, Long-term outcomes of peripheral atherectomy for femoropopliteal endovascular interventions., Eurointervention (2022) [10.4244/EIJ-D-22-00609] [abs].
  • Weissler, EH; Osazuwa-Peters, OL; Greiner, MA; Hardy, NC; Kougias, P; O'Brien, SM; Mark, DB; Jones, WS; Secemsky, EA; Vekstein, AM; Shalhub, S; Mussa, FF; Patel, MR; Vemulapalli, S, Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection., Jama Cardiol (2022) [10.1001/jamacardio.2022.4187] [abs].
  • O'Brien, EC; Mulder, H; Jones, WS; Hammill, BG; Sharlow, A; Hernandez, AF; Curtis, LH, Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial., Jama Cardiol (2022) [10.1001/jamacardio.2022.3844] [abs].
  • Harrington, J; Udell, JA; Jones, WS; Anker, SD; Bhatt, DL; Petrie, MC; Vedin, O; Sumin, M; Zwiener, I; Hernandez, AF; Butler, J, Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial., American Heart Journal, vol 253 (2022), pp. 86-98 [10.1016/j.ahj.2022.05.010] [abs].
  • Rao, SV; Kirsch, B; Bhatt, DL; Budaj, A; Coppolecchia, R; Eikelboom, J; James, SK; Jones, WS; Merkely, B; Keller, L; Hermanides, RS; Campo, G; Ferreiro, JL; Shibasaki, T; Mundl, H; Alexander, JH; PACIFIC AMI Investigators,, A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction., Circulation, vol 146 no. 16 (2022), pp. 1196-1206 [10.1161/CIRCULATIONAHA.122.061612] [abs].